Literature DB >> 25488908

Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center.

Tong Meng1, Huabin Yin1, Bo Li1, Zhenxi Li1, Wei Xu1, Wang Zhou1, Mo Cheng1, Jing Wang1, Lei Zhou1, Xinghai Yang1, Tielong Liu1, Wangjun Yan1, Dianwen Song1, Jianru Xiao1.   

Abstract

BACKGROUND: Chordoma in the spine is relatively rare, and minimal information has been published in the literature regarding this subject. Moreover, there are controversies over prognostic factors of this disease.
METHODS: A retrospective analysis of chordoma in the spine was performed by survival analysis. Local relapse-free survival (LRFS) and overall survival (OS) were analyzed from the date of surgery to the date of local recurrence and death. The LRFS and OS rates were estimated using the Kaplan-Meier method to identify potential prognostic factors. Factors with P values ≤ .1 were subjected to multivariate analysis by Cox regression analysis. P values ≤ .05 were considered statistically significant.
RESULTS: A total of 153 patients with spinal chordoma were included in the study. The mean follow-up period was 72.0 months (range, 1-279 months). Local recurrence was detected in 51 cases after initial surgery in our center, while death occurred in 42 cases. The statistical analysis suggested that tumor location of C3-L5, dedifferentiated chordoma, preoperative Frankel scores A-C, and total spondylectomy were independent prognostic factors for LRFS. In addition, total en bloc spondylectomy and Karnofsky' performance status (KPS) ≥ 80% were favorable factors for OS.
CONCLUSIONS: Total spondylectomy, by either en bloc or piecemeal method, could significantly reduce LRFS for spinal chordoma. Location of C3-L5 is a favorable factor for LRFS, while dedifferentiated subtype and preoperative Frankel scores A-C are adverse prognostic factors. In addition, total en bloc spondylectomy and KPS ≥ 80% significantly improve overall survival of patients with spinal chordoma.
© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  chordoma; prognostic factor; spine tumor; surgery; survival

Mesh:

Year:  2014        PMID: 25488908      PMCID: PMC4482860          DOI: 10.1093/neuonc/nou331

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  38 in total

1.  Chordoma: incidence and survival patterns in the United States, 1973-1995.

Authors:  M L McMaster; A M Goldstein; C M Bromley; N Ishibe; D M Parry
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

2.  Chordoma: natural history and results in 28 patients treated at a single institution.

Authors:  D Baratti; A Gronchi; E Pennacchioli; L Lozza; M Colecchia; M Fiore; M Santinami
Journal:  Ann Surg Oncol       Date:  2003-04       Impact factor: 5.344

3.  The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. I.

Authors:  H L Frankel; D O Hancock; G Hyslop; J Melzak; L S Michaelis; G H Ungar; J D Vernon; J J Walsh
Journal:  Paraplegia       Date:  1969-11

4.  Surgical strategy for spinal metastases.

Authors:  K Tomita; N Kawahara; T Kobayashi; A Yoshida; H Murakami; T Akamaru
Journal:  Spine (Phila Pa 1976)       Date:  2001-02-01       Impact factor: 3.468

5.  Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.

Authors:  P Bergh; L G Kindblom; B Gunterberg; F Remotti; W Ryd; J M Meis-Kindblom
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

6.  High amputation of the sacrum for extirpation of tumors. Principles and technique.

Authors:  B Stener; B Gunterberg
Journal:  Spine (Phila Pa 1976)       Date:  1978-12       Impact factor: 3.468

7.  In vitro characteristics of a sacrococcygeal chordoma maintained in tissue and organ culture systems.

Authors:  B C Horten; S R Montague
Journal:  Acta Neuropathol       Date:  1976-05-18       Impact factor: 17.088

Review 8.  Chordoma. A clinicopathologic study of metastasis.

Authors:  P W Chambers; C P Schwinn
Journal:  Am J Clin Pathol       Date:  1979-11       Impact factor: 2.493

9.  A system of staging musculoskeletal neoplasms.

Authors:  W F Enneking
Journal:  Clin Orthop Relat Res       Date:  1986-03       Impact factor: 4.176

10.  Long-term outcome following surgical treatment of sacral chordoma.

Authors:  Shunzo Osaka; Eiji Osaka; Toshio Kojima; Yukihiro Yoshida; Yasuaki Tokuhashi
Journal:  J Surg Oncol       Date:  2013-11-19       Impact factor: 3.454

View more
  23 in total

1.  The role of radiotherapy in the treatment of spinal chordomas: an integrative analysis of 523 cases.

Authors:  Li Yang; Harrison Xiao Bai; Ashley M Lee; Yingjie Zou; Bo Xiao; Jianhua Zhou; Paul Zhang
Journal:  Neuro Oncol       Date:  2015-10       Impact factor: 12.300

2.  Mobile spine chordoma: results of 166 patients from the AOSpine Knowledge Forum Tumor database.

Authors:  Ziya L Gokaslan; Patricia L Zadnik; Daniel M Sciubba; Niccole Germscheid; C Rory Goodwin; Jean-Paul Wolinsky; Chetan Bettegowda; Mari L Groves; Alessandro Luzzati; Laurence D Rhines; Charles G Fisher; Peter Pal Varga; Mark B Dekutoski; Michelle J Clarke; Michael G Fehlings; Nasir A Quraishi; Dean Chou; Jeremy J Reynolds; Richard P Williams; Norio Kawahara; Stefano Boriani
Journal:  J Neurosurg Spine       Date:  2015-12-18

3.  Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine.

Authors:  Ping Jiang; Xile Zhang; Weijuan Jiang; Na Meng; Abudureyimujiang Aili; Junjie Wang
Journal:  Cancer Biol Ther       Date:  2020-04-16       Impact factor: 4.742

4.  Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

Authors:  Ming-Xiang Zou; An-Bo Peng; Guo-Hua Lv; Xiao-Bin Wang; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

5.  Prognostic significance of pretreatment plasma D-dimer levels in patients with spinal chordoma: a retrospective cohort study.

Authors:  Bo Li; Hao Zhang; Pingting Zhou; Jiaxiang Yang; Haifeng Wei; Xinghai Yang; Cheng Yang; Zhipeng Wu; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-01-25       Impact factor: 3.134

6.  Surgical management of chordoma: A systematic review.

Authors:  Luca Denaro; Alessandra Berton; Mauro Ciuffreda; Mattia Loppini; Vincenzo Candela; Maria Luisa Brandi; Umile Giuseppe Longo
Journal:  J Spinal Cord Med       Date:  2018-07-26       Impact factor: 1.985

7.  Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival.

Authors:  S H Bakker; W C H Jacobs; W Pondaag; H Gelderblom; R A Nout; P D S Dijkstra; W C Peul; C L A Vleggeert-Lankamp
Journal:  Eur Spine J       Date:  2018-09-15       Impact factor: 3.134

Review 8.  En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review.

Authors:  Tong Meng; Wang Zhou; Bo Li; Huabin Yin; Zhenxi Li; Lei Zhou; Jinhai Kong; Wangjun Yan; Xinghai Yang; Tielong Liu; Dianwen Song; Jianru Xiao
Journal:  World J Surg Oncol       Date:  2015-05-08       Impact factor: 2.754

Review 9.  Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures.

Authors:  Jian Yang; Xinghai Yang; Wujun Miao; Qi Jia; Wei Wan; Tong Meng; Zhipeng Wu; Xiaopan Cai; Dianwen Song; Jianru Xiao
Journal:  World J Surg Oncol       Date:  2016-08-04       Impact factor: 2.754

10.  A comparative integrated multi-omics analysis identifies CA2 as a novel target for chordoma.

Authors:  Tong Meng; Runzhi Huang; Jiali Jin; Jianxuan Gao; Fuyan Liu; Ziheng Wei; Xiaowen Xu; Zhengyan Chang; Jun Lin; Na Ta; Zongqiang Huang; Huabin Yin; Wang Zhou; Dianwen Song
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.